SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline Release: Cervical Cancer Shot Shows Four-Year Benefits

February 23, 2006 | 
1 min read
GlaxoSmithKline's experimental cervical vaccine Cervarix provides 100 per cent protection over four years against cervical lesions, according to data presented on Tuesday.
Clinical research Phase III Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Podcast
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
August 26, 2025
 · 
1 min read
 · 
Jef Akst
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
 · 
1 min read
 · 
Lori Ellis
Glowing red neon heartbeat pulse rate line. Health and Medical concept. EKG Pulse Wave, cardiogram and rhythm
Duchenne muscular dystrophy
With Prasad Back at FDA, Capricor To Fight DMD Cardiomyopathy Rejection
August 20, 2025
 · 
7 min read
 · 
Heather McKenzie